<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02537158</url>
  </required_header>
  <id_info>
    <org_study_id>CH-GI-077</org_study_id>
    <nct_id>NCT02537158</nct_id>
  </id_info>
  <brief_title>Sorafenib and TACE as Adjuvant Therapy for MVI in HCC Patients After Radical Resection</brief_title>
  <official_title>Sorafenib and TACE as Adjuvant Therapy for MVI in HCC Patients After Radical Resection:a Non-randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective non-randomized controlled study. The purpose of this study is to
      evaluate the validity and safety of sorafenib and transcatheter arterial chemoembolization
      (TACE) for microvascular invasion (MVI) in hepatocellular carcinoma (HCC) patients after
      radical surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HCC is the sixth most common malignancy worldwide.Selected patients with HCC are candidates
      for potentially curative therapy, such as hepatic resection and liver transplantation.
      Nevertheless,tumor recurrence is 70 % at 5 years after resection and 15-30 % after liver
      transplantation,leading to tumor-related death.MVI is currently one of the most critical
      factors predictive of HCC recurrence.There are no approved effective interventional measures
      to improve the outcome of this patients with MVI.The purpose of this study is to explore the
      validity and safety of sorafenib and TACE for MVI in HCC patients after radical resection.The
      candidates will be assigned to sorafenib group (about 30 cases),TACE group (about 30
      patients) and control group (about 30 cases)，according to the willingness of the subject.All
      patients will be followed up for 3 years and Recurrence-free survival and overall survival
      will be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>recurrence-free survival</measure>
    <time_frame>36 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>36 month</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>sorafenib group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sorafenib group patients will accept sorafenib therapy for one year（400 mg bid,orally).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TACE group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TACE group patients will accept TACE therapy once at a month after resection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group patients will not accept any intervention,except necessary supportive treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>sorafenib group patients will accept sorafenib therapy for one year（400 mg bid,orally).</description>
    <arm_group_label>sorafenib group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TACE</intervention_name>
    <description>TACE group patients will accept TACE therapy once at a month after resection.</description>
    <arm_group_label>TACE group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-75 years of age;

          -  The liver tumor has been radically resected;

          -  Postoperative pathology proved to be hepatocellular carcinoma with negative margin and
             microvascular invasion;

          -  Imaging evaluations(CT/MRI) were performed at 1 month after the resection and no area
             of enhancement was seen;

          -  Child-Pugh A;

          -  Eastern Cooperative Oncology Group(ECOG) body condition score (PS) 0-1;

          -  Then patients understand and voluntarily signed a written informed consent;

        Exclusion Criteria:

          -  Recurrent HCC;

          -  pathology-proved multifocal HCC or HCC with satellite nodules;

          -  Tumor thrombus in portal vein or inferior vena cava trunk;

          -  Patients with extrahepatic metastasis found by radiologic or pathologic examination;

          -  severe dysfunction of the heart, kidney, or other organs.The patients cannot tolerate
             TACE or sorafenib after general assessment of the situation;

          -  Enrolled in other clinical study at the same time;

          -  Previously treated with other antitumor treatments except the resection;

          -  The researchers believe that the patient does not fit this study;

          -  Pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xinyu Bi, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>Cancer Hospital and Institute, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xinyu Bi, Doctor</last_name>
    <phone>86-13911792177</phone>
    <email>beexy1971@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital and Institute, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Bei jing</city>
        <zip>100026</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinyu Bi, Doctor</last_name>
      <phone>86-13911792177</phone>
      <email>beexy1971@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Rodríguez-Perálvarez M, Luong TV, Andreana L, Meyer T, Dhillon AP, Burroughs AK. A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability. Ann Surg Oncol. 2013 Jan;20(1):325-39. doi: 10.1245/s10434-012-2513-1. Epub 2012 Nov 13. Review.</citation>
    <PMID>23149850</PMID>
  </reference>
  <reference>
    <citation>Sumie S, Nakashima O, Okuda K, Kuromatsu R, Kawaguchi A, Nakano M, Satani M, Yamada S, Okamura S, Hori M, Kakuma T, Torimura T, Sata M. The significance of classifying microvascular invasion in patients with hepatocellular carcinoma. Ann Surg Oncol. 2014 Mar;21(3):1002-9. doi: 10.1245/s10434-013-3376-9. Epub 2013 Nov 20.</citation>
    <PMID>24254204</PMID>
  </reference>
  <reference>
    <citation>Roayaie S, Blume IN, Thung SN, Guido M, Fiel MI, Hiotis S, Labow DM, Llovet JM, Schwartz ME. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology. 2009 Sep;137(3):850-5. doi: 10.1053/j.gastro.2009.06.003. Epub 2009 Jun 12.</citation>
    <PMID>19524573</PMID>
  </reference>
  <reference>
    <citation>Zhu YB, Xu X, Zheng SS. [Association of microvascular invasion with recurrence and prognosis of patients with small hepatocellular carcinoma undergoing liver transplantation]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2014 Nov;43(6):658-63. Chinese.</citation>
    <PMID>25644564</PMID>
  </reference>
  <reference>
    <citation>Shirabe K, Toshima T, Kimura K, Yamashita Y, Ikeda T, Ikegami T, Yoshizumi T, Abe K, Aishima S, Maehara Y. New scoring system for prediction of microvascular invasion in patients with hepatocellular carcinoma. Liver Int. 2014 Jul;34(6):937-41. doi: 10.1111/liv.12459. Epub 2014 Jan 24.</citation>
    <PMID>24393295</PMID>
  </reference>
  <reference>
    <citation>Meniconi RL, Komatsu S, Perdigao F, Boëlle PY, Soubrane O, Scatton O. Recurrent hepatocellular carcinoma: a Western strategy that emphasizes the impact of pathologic profile of the first resection. Surgery. 2015 Mar;157(3):454-62. doi: 10.1016/j.surg.2014.10.011. Epub 2014 Nov 6.</citation>
    <PMID>25633732</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2015</study_first_submitted>
  <study_first_submitted_qc>August 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2015</study_first_posted>
  <last_update_submitted>March 13, 2016</last_update_submitted>
  <last_update_submitted_qc>March 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Xinyu Bi</investigator_full_name>
    <investigator_title>Xinyu Bi</investigator_title>
  </responsible_party>
  <keyword>sorafenib</keyword>
  <keyword>transcatheter arterial chemoembolization</keyword>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>microvascular invasion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

